ASPirin in Reducing Events in the Elderly (ASPREE)
ASPREE is a 5 year primary prevention clinical trial aimed at assessing whether daily treatment of aspirin prolongs healthy lifespan through the prevention of heart attack, stroke, cognitive decline, physical decline and some cancers such as bowel cancer. ASPREE is an international multicentre trial which will be conducted in general practice in Australia and clinical trial centres and primary care clinics in the United States.
ASPREE is a randomised trial, meaning participants are randomly allocated to a type of treatment, either aspirin or a placebo.
A placebo is an inactive, harmless substance containing no medication.
Men and women are eligible to take part of this study if they are:
Unfortunately people cannot take part in this trial if they: